XBiotech (XBIT) EBITDA Margin (2020 - 2022)

XBiotech (XBIT) posted quarterly EBITDA Margin of 2720.67% for Q4 2022, down 615.4% quarter-over-quarter from 380.3% in Q3 2022.

XBiotech (XBIT) EBITDA Margin (2020 - 2022) Analysis & Trends

XBiotech's EBITDA Margin history runs 3 years deep, the most recent figure standing at 2720.67% for Q4 2022.

In Q4 2022, EBITDA Margin changed N/A year-over-year to 2720.67%; the TTM figure through Sep 2023 stood at 12361.67% (down 1195431.0% YoY), while the FY2022 annual figure was 860.1%, down 72374.0% from the prior year.
EBITDA Margin for Q4 2022 stood at 2720.67%, down from 380.3% in the prior quarter.
The five-year high for EBITDA Margin was 14.38% in Q4 2020, with the low at 2720.67% in Q4 2022.
The 3-year median for EBITDA Margin is 82.56% (2021), against an average of 539.97%.
The sharpest annual moves came in 2021 and 2022: EBITDA Margin plunged 3829 bps in 2021, then tumbled 149574 bps in 2022.
XBiotech's EBITDA Margin stood at 14.38% in 2020, then slumped by 674 bps to 82.56% in 2021, then plunged by 3195 bps to 2720.67% in 2022.
Business Quant data shows XBIT's EBITDA Margin at 2720.67% in Q4 2022, 380.3% in Q3 2022, and 790.46% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	XBiotech	68.90 Mn	68.90 Mn	-	-

Download Data